Physician profile
Roberto A Lopez
NPI 1124306436
$3,812.23
in general payments reported to CMS, 2019-2025
31 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $637 · 2021: $450 · 2022: $864 · 2023: $754 · 2024: $585 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.62 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $434.07 | 2019-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $328.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $289.65 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $268.17 | 2022-2024 | |
| Glaxosmithkline, LLC. | $230.11 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $216.91 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.46 | 2019-2023 | Stiolto Respimat |
| Astellas Pharma US INC | $142.00 | 2019-2024 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $127.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $126.97 | 2019-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $113.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.89 | 2019-2022 | |
| Boston Scientific Corporation | $103.59 | 2022-2024 | Watchman Flx |
| Amarin Pharma, INC. | $103.44 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $65.79 | 2020-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $59.28 | 2019-2022 | |
| Grt US Holding, INC. | $54.67 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $53.71 | 2024 | Gemtesa |
| Ibsa Pharma INC. | $46.00 | 2020 | |
| Genentech USA, INC. | $44.93 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.16 | 2022 | |
| Sunovion Pharmaceuticals INC. | $37.88 | 2021 | |
| Radius Health, INC. | $27.13 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $20.37 | 2022 | |
| Horizon Therapeutics Plc | $15.58 | 2023 | Krystexxa |
| Eisai INC. | $14.97 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.63 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.